Bibliografisk note

Funding Information:
We thank Adrian P. Bracken, Katrin Ottersbach, Kim B. Jensen, and members of the Pollard lab for helpful discussions and critical reading of the manuscript. Abdenour Soufi provided technical advice on ChIP-seq protocols, and Angel Montero Carcaboso generously provided the patient-derived cell line pGBM002 (HSJD-GBM-002). We are grateful to the University College London Cancer Institute Genomics core facility for performing the next-generation mRNA sequencing and to the Wellcome Trust for providing the mass spectrometry large equipment (Multiuser Equipment Grant 208402/Z/17/Z ). Primary fetal NSCs were provided by the Glioma Cellular Genetics Resource ( www.gcgr.org.uk ). The project was supported by a grant from the Children with Cancer UK Charity ( 15/189 ). R.B.B. was supported by a PhD fellowship from the Science Without Borders Program (CAPES, Governo Dilma Rousseff, Brazil) and a postdoctoral fellowship from the European Molecular Biology Organization (EMBO). G.M.M. was supported by the Cancer Research UK Centre Accelerator Award ( A21922 ). S.M.P is a Cancer Research UK Senior Research Fellow ( A17368 ).

Funding Information:
We thank Adrian P. Bracken, Katrin Ottersbach, Kim B. Jensen, and members of the Pollard lab for helpful discussions and critical reading of the manuscript. Abdenour Soufi provided technical advice on ChIP-seq protocols, and Angel Montero Carcaboso generously provided the patient-derived cell line pGBM002 (HSJD-GBM-002). We are grateful to the University College London Cancer Institute Genomics core facility for performing the next-generation mRNA sequencing and to the Wellcome Trust for providing the mass spectrometry large equipment (Multiuser Equipment Grant 208402/Z/17/Z). Primary fetal NSCs were provided by the Glioma Cellular Genetics Resource (www.gcgr.org.uk). The project was supported by a grant from the Children with Cancer UK Charity (15/189). R.B.B. was supported by a PhD fellowship from the Science Without Borders Program (CAPES, Governo Dilma Rousseff, Brazil) and a postdoctoral fellowship from the European Molecular Biology Organization (EMBO). G.M.M. was supported by the Cancer Research UK Centre Accelerator Award (A21922). S.M.P is a Cancer Research UK Senior Research Fellow (A17368). R.B.B. and S.M.P. conceived the project and designed the experiments. R.B.B. performed the majority of the bench-based experimentation and data analyses. B.S. J.A. and S.T. performed the bioinformatic analyses. N.A. L.B. and M.A.M.-T. performed xenotransplantations and histological analyses. C.B. performed immunoprecipitations and western blotting procedures. J.C.W. and A.K. performed MS analysis. K.M.F and F.R. performed FOXG1 loss-of-function experiments. V.G. C.A.C.W. K.M.F. and G.M.M. provided technical assistance with derivation and characterization of cell lines, and R.A.A. provided human fetal tissues. R.B.B. and S.M.P. co-wrote the manuscript. S.M.P. is a founder and shareholder of Cellinta Ltd. a biotechnology startup that is developing cancer therapeutics, including glioblastoma. S.M.P. is also an inventor on a University of Edinburgh patent related to NSC culture methods (WO2005121318A3). The other authors declare no competing interests.

Publisher Copyright:
© 2021 The Authors